Skip to main content
Publications
Lapuerta P, Joish V, Ervin C , Evans E, Reaney M, Preblick R, De Fanti B, Castro R, DiBenedetti D . Patients with type 1 diabetes value increased glucose stability and associate it with improved well-being: exit interviews from Sotagliflozin Phase 3 study . Poster presented at the 2018 European Association for the Study of Diabetes (EASD) Conference; October 2, 2018. Berlin, Germany.
Anthony L, Ervin C , Lapuerta P, Kulke MH, Kunz P, Bergsland E, Horsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Oberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB . Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl . Clin Ther. 2017 Nov 11;39(11):2158-68. doi: 10.1016/j.clinthera.2017.09.013
Mansfield C , Bullok KE, Fuhs JV, Kahle-Wrobleski K, Tockhorn-Heidenreich A, Andrews JS, DiBenedetti DB , Matthews BR, Darling JC, Siemers ER, Hauber AB. The patient voice: exploring treatment preferences in participants with mild cognitive concerns to inform regulatory decision-making . Poster presented at the 2017 Alzheimer’s Association International Conference; July 19, 2017. London, United Kingdom.
Anthony L, Horsch D, Ervin C , Kulke MH, Pavel M, Bergsland E, Caplin M, Oberg K, Warner R, Kunz P, Metz DC, Pasieka J, Pavlakis N, DiBenedetti D , Haydysch E, Yang QM, Jackson S, Arnold K, Law L, Lapuerta P. Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: patient exit interviews . Poster presented at the 2016 UKI NETS 14th National Conference; December 2016. London, UK. [abstract] Pancreas. 2016 Dec; 45(3):470. Previously presented at the 8th Symposium of the North American Neuroendocrine Tumor Society. doi: 10.1530/endoabs.46.P11
Pavel M, Horsch D, Anthony L, Ervin C , Kulke MH, Bergsland E, Caplin M, Oberg K, Warner R, Kunz P, Metz DC, Pasieka J, Pavlakis N, DiBenedetti D , Lapuerta P. Patient interviews in TELESTAR, a phase 3 study of telotristat etiprate, report meaningful improvement in carcinoid syndrome . Poster presented at the 2016 European Neuroendocrine Tumor Society (ENETS) Annual Meeting; March 2016. Barcelona, Spain. [abstract] Neuroendocrinology. 2016; 103:89.
Anthony L, Horsch D, Ervin C , Kulke MH, Pavel M, Bergsland E, Caplin M, Oberg K, Warner R, Kunz P, Metz DC, Pasieka J, Pavlakis N, DiBenedetti D , Haydysch E, Yang QM, Jackson S, Arnold K, Law L, Lapuerta P. Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: patient exit interviews . Poster presented at the 8th Symposium of the North American Neuroendocrine Tumor Society; October 15, 2015. Austin, TX.
Francois C, Danchenko N, Williams VS , Nelson LM , Williams NJ, Yarr SR , DiBenedetti DB , Lancon C. Psychometric evaluation of the depression and family functioning scale (DFFS) . Poster presented at the Second Meeting on Patient Reported Outcomes and Person Centered Care in Mental Health – Diagnosis, Prevention and Treatment in Mental Health: Effectiveness and Comparative Effectiveness; September 26, 2014. Washington, DC. [abstract] J Ment Health Policy Econ. 2014 Sep; 17(Suppl 1):S5-6.